CD19 and non-Hodgkin lymphoma: One recent Phase I clinical trial targeted CD19+ non-Hodgkin's lymphoma and chronic lymphocytic leukemia by infusion of retrovirus-transduced anti-CD19 CAR cord blood NK cells.